Table 3 Correlation between the clinicopathological characteristics and expression of ELF and TGF-β1 in the 84 HCC patients
From: The prognostic value of combined TGF-β1 and ELF in hepatocellular carcinoma
Variables | Cases | ELF expression | P value | TGF-β1 expression | P value | ||
|---|---|---|---|---|---|---|---|
Low | High | Low | High | ||||
Age(yrs) | |||||||
> = 60 | 16 | 7(43.8%) | 9(56.2%) | 0.442 | 9(54.4%) | 7(54.4%) | 0.325 |
<60 | 68 | 37(54.4%) | 31(45.6%) | 29(42.6%) | 39(57.4%) | ||
Sex | |||||||
Male | 68 | 37(54.4%) | 31(45.6%) | 0.44 | 27(39.7%) | 41(60.3%) | 0.77 |
Female | 16 | 7(43.8%) | 9(56.2%) | 7(43.8%) | 9(56.2%) | ||
HCC family history | |||||||
Yes | 6 | 2(33.3%) | 4(66.7%) | 0.83 | 3(50.0%) | 3(50.0%) | 0.95 |
No | 78 | 42(53.8%) | 36(46.2%) | 31(39.7%) | 47(60.3%) | ||
HbsAg | |||||||
Positive | 72 | 41(56.9%) | 31(43.1%) | 0.04 | 29(40.3%) | 43(59.7%) | 0.93 |
Negative | 12 | 3(25.0%) | 9(75.0%) | 5(41.7%) | 7(58.3%) | ||
ALT(U/L) | |||||||
≥80 | 9 | 3(33.3%) | 6(66.7%) | 0.39 | 1(11.1%) | 8(88.9%) | 0.12 |
<80 | 75 | 41(54.7%) | 34(45.3%) | 33(44.0%) | 42(56.0%) | ||
PLT(×109) | |||||||
>100 | 74 | 41(55.4%) | 33(44.6%) | 0.24 | 28(37.8%) | 46(62.2%) | 0.32 |
≤100 | 10 | 3(30.0%) | 7(70.0%) | 6(60.0%) | 4(40.0%) | ||
Cirrhosis | |||||||
Yes | 64 | 32(50.0%) | 32(50.0%) | 0.43 | 27(42.2%) | 37(57.8%) | 0.57 |
No | 20 | 12(60.0%) | 8(40.0%) | 7(35.0%) | 13(65.0%) | ||
AFP(ug/L) | |||||||
≥20 | 48 | 28(58.3%) | 20(41.7%) | 0.21 | 19(39.6%) | 29(60.4%) | 0.85 |
<20 | 36 | 16(44.4%) | 20(55.6%) | 15(41.7%) | 21(58.3%) | ||
Tumor size (cm) | |||||||
≥5 | 50 | 32(64.0%) | 18(36.0%) | 0.01 | 13(26.0%) | 37(74.0%) | 0.001 |
<5 | 34 | 12(35.3%) | 22(64.7%) | 21(61.8%) | 13(38.2%) | ||
Tumor number | |||||||
Single | 62 | 26(41.9%) | 36(58.1%) | 0.001 | 31(50.0%) | 31(50.0%) | 0.003 |
Multiple | 22 | 18(81.8%) | 4(18.2%) | 3(13.6%) | 19(86.4%) | ||
Differentiation | |||||||
I-II | 62 | 31(50.0%) | 31(50.0%) | 0.46 | 27(43.5%) | 35(56.5%) | 0.34 |
III-IV | 22 | 13(59.1%) | 9(40.9%) | 7(31.8%) | 15(68.2%) | ||
TNM stage | |||||||
I-II | 55 | 24(43.6%) | 31(56.4%) | 0.03 | 29(52.7%) | 26(47.3%) | 0.002 |
III-IV | 29 | 20(69.0%) | 9(31.0%) | 5(17.2%) | 24(82.8%) | ||
PVTT | |||||||
Yes | 11 | 8(72.7%) | 3(27.3%) | 0.15 | 2(18.2%) | 9(81.8%) | 0.11 |
No | 73 | 36(49.3%) | 37(50.7%) | 32(43.8%) | 41(56.2%) | ||
Tumor encapsulation | |||||||
Complete | 64 | 30(46.9%) | 34(53.1%) | 0.07 | 29(45.3%) | 35(54.7%) | 0.11 |
None | 20 | 14(70.0%) | 6(30.0%) | 5(25.0%) | 15(75.0%) | ||
Recurrence | |||||||
Yes | 56 | 39(69.6%) | 17(30.4%) | <0.001 | 12(21.4%) | 44(78.6%) | <0.001 |
No | 28 | 5(17.9%) | 23(82.1%) | 22(78.6%) | 6(21.4%) | ||
Complication | |||||||
No | 73 | 41(56.2%) | 32(43.8%) | 0.07 | 31(42.5%) | 42(57.5%) | 0.34 |
Yes | 11 | 3(27.3%) | 8(72.7%) | 3(27.3%) | 8(72.7%) | ||